Background {#Sec1}
==========

High penetrance inherited breast cancer is mainly caused by pathogenic mutations in the *BRCA1* and *BRCA2* genes. When these genes were identified, it soon became clear that breast cancer in women with pathogenic mutations in *BRCA1* had worse prognostic features compared with women carrying pathogenic *BRCA2* mutations who have tumours more reflective of breast cancer in the general population although still with a marginally increased level of high grade tumours \[[@CR1]--[@CR3]\]. Whilst strongly associated with triple negative breast cancer, most young patients with this breast cancer subtype do not carry pathogenic *BRCA1* mutations \[[@CR4]\]. Additionally the vast majority of older women with familial breast cancers with good prognostic markers and good prognosis do not carry pathogenic *BRCA2* mutations \[[@CR5]\]. The majority of families with smaller aggregations of breast cancer do not yet have demonstrable underlying genetic defects and the majority of carriers of pathogenic mutations in *BRCA1* and *BRCA2* do not have strong aggregation of breast cancer in their families \[[@CR6]\]. Although caused by genes involved in homologous DNA repair, breast cancers caused by *BRCA1* and *BRCA2* mutations appear to be rather different diseases.

Initially, all carriers of pathogenic *BRCA1/2* mutations were advised to be mammographically screened from a young age \[[@CR1]\]. However the prognosis for *BRCA1*-associated breast cancer remained serious despite early mammography surveillance \[[@CR7]\]. Consequently. Magnetic Resonance Imaging (MRI) was advised to improve early diagnosis, and with resultant downstaging of tumours at diagnosis being demonstrated \[[@CR8]--[@CR12]\]. This lead to hope for improved survival \[[@CR13]\] based on projection of observations of tumours in patients without demonstrated *BRCA1* mutations, assuming that their biology and response to treatment were similar. A validation of this hope based on empirical observed outcome of MRI screening in *BRCA1* carriers is, however, still lacking - besides a few reports indicating that it may not be the case \[[@CR14], [@CR15]\].

The prevalence of pathogenic *BRCA2* mutations in breast cancer cases is, however, less than for *BRCA1* in most of Western Europe and North America, which may be why reports on the outcome of early diagnosis with MRI in carriers of pathogenic *BRCA2* mutations are even sparser. This is presumed to be why many reports on the effects of early diagnosis on inherited breast cancer have combined *BRCA1* and *BRCA2* mutation carriers together to provide sufficient enough cases to arrive at a significant conclusion. However, by combining two biologically different groups of tumours, the average may not be true for individual patients. We previously reported that the outcome of early diagnosis with mammography and MRI for carriers of pathogenic *BRCA1* mutations \[[@CR16]\] was not as good as was hoped for. We now report that the observed outcome of mammography and MRI in the carriers of pathogenic *BRCA2* mutations was better: the outcome in screened women carrying a pathogenic *BRCA2* variant was significantly superior to non-screened controls.

Material and methods {#Sec2}
====================

Randomised control trials of screening in *BRCA2* mutation carriers are not feasible given the evidence that MRI screening has been shown to be effective at early detection with small more node negative cancers identified \[[@CR8]--[@CR12]\] and offering less than indicated in the current guidelines was considered unacceptable. We therefore assessed our prospective screening in *BRCA2* mutation carriers compared with an unscreened pragmatic control group. Women unaffected by breast cancer undergoing either annual mammography or combined annual mammography and MRI breast screening with pathogenic mutations in the *BRCA2* gene at time of breast cancer diagnosis or who later became identified from post-diagnosis testing were eligible for this study. Screening took place at the Genesis Prevention Centre in Manchester and in the regional hospitals in Norway where Oslo University Hospital served the majority of the mutation carriers between 1990 and 2014. Known *BRCA2* mutation carriers aged 30--50 years were offered annual mammography from 1996 (there are some prospective data with mammography from 1990 in women later found to be *BRCA2* mutation carriers) with the addition of MRI from 1997 (aged 30--50 years) with 12--18 monthly mammography after age 50 in the Manchester series. In the Norwegian series carriers were offered annual mammography combined with MRI from 25 to 70 years of age from 2001 onwards. Before MRI was available, and in cases where the *BRCA2* mutation was not detected until later, all *BRCA2* mutation carriers were subject to annual mammography without MRI in both Manchester and Norway \[[@CR7]\]. All women were followed prospectively from breast cancer diagnosis. In Manchester age at last follow up or death was determined from hospital notes or the North West Cancer Intelligence Service (NWCIS) in October 2012 and NHS tracing in June 2014. Cause of death was established from NWCIS. In Norway, the outpatient genetic clinic in Oslo referred all patients for each single screening examination. Resultant screening reports and other outcomes, including follow-up after cancer diagnosis and causes of death were noted in the medical files. All prospectively detected cases had blood samples stored to be analysed later with updated methods if no mutation was detected initially. All women with prospective breast cancer were offered full *BRCA1/2* testing with sequencing and Multiple Ligation dependant Probe Amplification (MLPA). In Manchester, 22/302 (7.3 %) prospective breast cancers had not been tested, but there were only two deaths in the non-tested group. None of the Norwegian women with breast cancer were untested.

The pragmatic controls were diagnosed between 1996 and 2014 and were obtained from the Manchester Regional Genetic Register for *BRCA2*. Controls had only undergone population 3-yearly screening by mammography from 50 to 69 years of age or had not undergone radiological surveillance at all. Mutation testing was carried out after diagnosis, sometimes up to 10-years later. Follow-up from diagnosis to death or last known date living was as above. Survival curves were compared by Kaplan-Meier analysis.

Results {#Sec3}
=======

Combining the published series from Manchester and Oslo increases the number of *BRCA2* mutation carriers diagnosed with breast cancer in a combined MRI/mammography programme from 20 to 34 when only women unaffected with breast cancer at entry are included \[[@CR15], [@CR16]\]. Similarly, the mammography group was expanded from 30 to 53 women from the UK report \[[@CR16]\] (Table [1](#Tab1){ref-type="table"}). There were 8 interval cancers in the mammography alone group and two in the combined group one of which was a 13 mm node negative invasive cancer found at risk reducing mastectomy. There were 274 carriers identified in the comparison group of which 260 had invasive breast cancer. There have been no deaths in the MRI group. Age at diagnosis ranged from 33 to 74 years (median 43) and there were 180 years of follow up (range 0.0-13.1; mean 5.3; median 4.0). In the mammography alone group, age at diagnosis ranged from 28 to 77 years (median 48) and there were 404 years of follow up (range 0.3--19.4; mean 7.6; median 6.7). There were six deaths in the mammography group, five from breast cancer and one from primary lung cancer. Median date at diagnosis was 04/2006 in the screened group with first cancer identified in 1993, although the first MRI detected cancer was in 2000. The controls were diagnosed aged 22--72 years (median 46.1) with 1525.one years of follow up (range 0--16.6; mean 5.56; median 4.7). Median date at diagnosis was 04/2003. There were 41 deaths: 37 from breast cancer, three from ovarian cancer, and one from heart disease.Table 1Combined MRI/mammography, mammography and unscreened *BRCA2* mutation carriers survival from diagnosisNumber10-year survival all causes (95 % CI)Log Rank (Mantel-Cox) *P* value for overall survival compared to unscreened10-year survival breast cancer (95 % CI)Log Rank (Mantel-Cox) *P* value overall survival compared to unscreenedUnscreened27470.8 (62.2 to 79.4)74.6 (66.6 to 82.6)MRI/mammography34100 %0.026100 %0.0356 prevalent26 incident2 IntervalMammography5385.5 (72.6 to 98.4)0.14285.5 (72.6 to 98.4)0.1969 prevalent36 incident8 IntervalAny screening87 (5 detected on mammography only in MRI group and 6 with both modalities)89.5 (79.5 to 99.5)0.01789.5 (79.5 to 99.5)0.029

Ten-year overall and breast cancer specific survival was 100 % in the combined group and 85.5 % in the mammography group and 70.8 % and 74.6 % respectively in the controls (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). There were 16 alive without metastasis in the MRI group with more than 5-years follow up and nine with more than nine years follow up. Ten-year survival was 89.8 % in those *BRCA2* mutation carriers undergoing any form of intensive (mammography only or combined) screening compared with 74.6 % in controls (*p* = 0.026). Breast cancer specific survival remained significantly better at 20 years (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Breast cancer specific survival on Kaplan-Meier analysis for combined MRI and mammography versus no intensive screeningFig. 2Kaplan-Meier survival plot for breast cancer specific deaths for those BRCA2 mutation carriers undergoing any intensive screening versus no additional screening (*p* = 0.029)

Tumour characteristics are presented in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Pathology was only available for grade on 175/260 (67 %) and for tumour size on 127/260 (49 %) of controls since many were diagnosed in other hospitals in the UK. However, the dates of diagnosis and whether they had invasive disease was known from cancer registration data for all controls. Tumours in the screened group were more likely to be DCIS: 19/87 (21.8 %) versus 14/274 in the comparison group (5.1 %) (*p* \< 0.001). Invasive tumours in screened cases were significantly smaller (*p* = 0.002) and more likely to be node negative (Table [3](#Tab3){ref-type="table"}: *p* = 0.001). The main driver of mortality appeared to be lymph node status; there was 83 % 10-year survival in node negative disease compared to 68 % for those with positive nodes (*p* = 0.019). Node negative screened cases did extremely well with 96 % 10-year survival compared to 72 % for node positive screened cases (*p* = 0.049). Surprisingly, tumour size and grade did not predict survival, although this may be confounded by the low proportion of unscreened women (among whom most of the deaths occurred) with full pathology data available. Age also appeared to have no effect in either the screened or unscreened groups.Table 2Tumour and age characteristics in intensively screened and unscreened womenMRI/mammographyMammographyNo screeningTotal*p* valueIn situ (*n* = 33, 79.1 %)Ductal10 (100)9 (100)14 (100)33 (100)1.0Lobular0 (0)0 (0)0 (0)0 (0)Invasive breast cancer (*n* = 328, 90.9 %)Type (*n* = 328)Ductal24 (96.0)41 (95.3)244 (93.8)309 (94.2)Lobular1 (4.0)1 (2.3)16 (6.2)18 (5.5)Mixed0 (0)1 (2.3)0 (0)1 (0.3)Age groups (*n* = 328)\<50 years17 (68.0)23 (53.5)168 (64.6)208 (63.4)0.330\> = 50 Years8 (32.0)20 (46.5)92 (35.4)120 (36.6)Nodes (*n* = 148)018 (78.3)23 (60.5)34 (39.1)75 (50.7)12 (8.7)8 (21.1)17 (19.5)27 (18.2)2--31 (4.3)6 (15.8)17 (19.5)24 (16.2)4--50 (0)1 (2.6)9 (10.3)10 (6.8)6+2 (8.7)0 (0.0)10 (11.5)12 (8.1)Missing25173180Nodes (*n* = 148)Negative18 (78.3)23 (60.5)34 (39.1)75 (50.7)0.001Positive5 (21.7)15 (39.5)53 (60.9)73 (49.3)ER-status (*n* = 211)Negative3 (18.8)11 (27.5)34 (21.9)48 (22.7)0.698Positive13 (81.3)29 (72.5)121 (78.1)163 (77.3)Missing93105117Grade (*n* = 237)11 (4.3)4 (10.3)6 (3.4)11 (4.6)211 (47.8)15 (38.5)63 (36.0)89 (37.6)311 (47.8)20 (51.3)106 (60.6)137 (57.8)Missing248691Grade (*n* = 237)1/212 (52.2)19 (48.7)69 (39.4)100 (42.2)0.338311 (47.8)20 (51.3)106 (60.6)137 (57.8)Censored (*n* = 328)Alive25 (100)38 (88.4)222 (85.4)285 (86.9)0.112Dead0 (0.0)5 (11.6)38 (14.6)43 (13.1)Size (*n* = 186)\<109 (42.9)10 (26.3)9 (7.1)28 (15.1)10 -- 19.98 (38.1)17 (44.7)55 (43.3)80 (43.0)20 -- 29.93 (14.3)9 (23.7)36 (28.3)48 (25.8)30 -- 39.90 (0.0)1 (2.6)12 (9.4)13 (7.0)40 -- 49.90 (0.0)1 (2.6)7 (5.5)8 (4.3)\> = 501 (4.8)0 (0.0)8 (6.3)9 (4.8)Missing45133142Size (*n* = 186)\<2017 (81.0)27 (71.1)64 (50.4)108 (58.1)0.006\> = 204 (19.0)11 (28.9)63 (49.6)78 (41.9)Table 3Invasive cancers by tumour characteristics with all cause survivalSelectionNumber of casesNumber of deaths5 years survival (SE)10 years survival (SE)*p* value for 2^nd^ category (e.g. \<50 vs 50+)*p* value for screened vs no screening for each categoryNo screening260380.871 (0.025)0.728 (0.043)0.089Screened6850.917 (0.040)0.863 (0.065)All (*n* = 328) \<50 year208250.895 (0.025)0.795 (0.040)0.117 50+ yrs120180.853 (0.040)0.647 (0.088)Screened \<50 year4030.941 (0.041)0.869 (0.079)0.6900.216 50+ yrs2820.867 (0.088)0.867 (0.088)0.214No screening \<50 year168220.883 (0.030)0.777 (0.045)0.121 50+ yrs92160.847 (0.045)0.570 (0.111)All (*n* = 211) ER neg4830.913 (0.048)0.913 (0.048)0.130 ER pos163230.909 (0.028)0.686 (0.064)Screened ER neg140110.1460.238 ER pos4250.862 (0.065)0.755 (0.116)0.694Not screened ER neg3430.875 (0.068)0.875 (0.068)0.375 ER pos121180.925 (0.030)0.665 (0.074)All (*n* = 237) Grade 1/2100120.892 (0.039)0.740 (0.076)0.943 Grade 3137180.887 (0.032)0.776 (0.050)Screened Grade 1/23120.900 (0.067)0.900 (0.067)0.9800.248 Grade 33120.920 (0.055)0.920 (0.055)0.185No screening Grade 1/269100.889 (0.047)0.668 (0.101)0.958 Grade 3106160.876 (0.039)0.729 (0.062)All (*n* = 148) Node neg (0)7550.958 (0.029)0.829 (0.076)**0.019** Node pos (1+)73140.823 (0.054)0.676 (0.077)Screened Node neg (0)4110.962 (0.038)0.962 (0.038)**0.049**0.209 Node pos (1+)2040.821 (0.094)0.718 (0.127)0.706No screening Node neg (0)3440.955 (0.044)0.728 (0.123)0.164 Node pos (1+)53100.822 (0.067)0.667 (0.089)All (*n* = 186) \<20 mm108140.922 (0.029)0.752 (0.058)0.884 20 + mm78100.865 (0.048)0.778 (0.064)Screened \<20 mm4440.909 (0.051)0.818 (0.098)0.6240.441 20 + mm1510.917 (0.080)0.917 (0.080)0.277No screening \<20 mm64100.939 (0.034)0.717 (0.086)0.792 20 + mm6390.849 (0.057)0.731 (0.081)Bold type indicates statistically significant results

*BRCA2* status was established on average six years post breast cancer diagnosis in the controls, with a median time of 4.7 years. HER2 data was only available on a small proportion of women from each group as HER2 testing was not fully implemented until 2006.

However, only around 7 % of *BRCA2* carriers known in Manchester (12/175) are HER2 positive and only one of the screened cases was known to be HER2 positive.

Discussion {#Sec4}
==========

Although there is evidence for a projected improvement in survival from annual mammography screening in familial breast cancer (from those largely at low risk of *BRCA1/2*) under 50 years of age \[[@CR17], [@CR18]\], this is the first time that a prospectively observed reasonably large series of *BRCA2* carriers has been shown to have an apparent survival advantage from annual screening. Recently a Dutch group showed no improvement in survival, based on only two deaths out of 18 *BRCA2* related breast cancers compared to three events in controls \[[@CR19]\]. Nonetheless the same group reported that annual mammography screening beyond 60 years of age in *BRCA1/2* carriers is associated with a marked improvement in tumour stage at diagnosis, with 58 % diagnosed at stage two or above with usual two-yearly screening compared to only 21 % in the annual group \[[@CR20]\]. Additionally, the interval cancer rate was doubled by extending screening to two years. The data from this and the present study concur with NICE guidelines in England and Wales who recommend annual mammography for *BRCA1/2* carriers until 70 years of age \[[@CR21]\]. Although the present study has used a pragmatic comparison group of *BRCA2* carriers not undergoing intensive screening a true matched control series would be impossible as women who knew they were mutation carriers would be very unlikely to not undergo added surveillance.

The current situation is that no single centre has a series large enough and well enough constructed and documented to provide a definitive answer to the question of whether MRI breast screening improves survival in *BRCA2* mutation carriers. This is why close to all major organisations world-wide addressing these questions have organised 'THE BRCA CHALLENGE' (<http://www.humanvariomeproject.org/brca-challenge.html>) which at the 2015 meeting in the UNESCO centre in Paris called for a broad international collaboration to provide answers to the unanswered questions. In this context we report our findings and encourage others to do the same, so as to move our knowledge on effects of interventions to prevent *BRCA2*-associated breast cancer death from assumptions to empirical observed effects of interventions. Until the time when more definitive answers are available female *BRCA2* carriers will still require guidance on whether surveillance with MRI and mammography offers similar improvements in life expectancy than can be gained from risk reducing surgery \[[@CR13], [@CR22]\].
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Novelty and impact {#FPar1}
==================

The paper provides convincing evidence for improved survival for *BRCA2* mutation carriers undergoing MRI screening. All women with a *BRCA2* mutation should be offered annual MRI screening.
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